For example, in NSCLC patients with mutations in driver genes such as EGFR, ALK, and ROS1, after resistance to first‐ and second‐generation TKIs, even upon receiving third‐ or fourth‐generation drugs, the targeting of driver gene signals persists, and some patients still respond effectively.300, 301. The gene discussed is ALK; the disease is non-small cell lung carcinoma.